Fig. 3: Qβ-PHF1 vaccination reduces soluble pathological tau in the brains of rTg4510 mice, while Qβ-AT8 vaccination does not.
From: pS396/pS404 (PHF1) tau vaccine outperforms pS199/pS202 (AT8) in rTg4510 tauopathy model
a Western blot of soluble hippocampal lysates from Qβ Control and Qβ-PHF1 vaccinated rTg4510 mice were evaluated for markers of phosphorylated (AT8, AT180, PHF1) and total tau (Tau5). All samples were run on the same gel. b Compared to Qβ Control vaccinated mice, Qβ-PHF1 vaccinated mice showed a significant reduction in pathological AT180+ tau without any reduction in total physiologic tau. c. Immunohistochemistry of brain sections from Qβ Control and Qβ-PHF1 vaccinated rTg4510 mice staining for AT180 tau pathology in the cerebral cortex (CTX) and CA1 hippocampus. d There was a significant reduction in AT180+ tau pathology in both the cortex and hippocampus of Qβ-PHF1 vaccinated mice compared to Qβ Control mice (e, f). Western blot of soluble hippocampal lysates from Qβ Control and Qβ-AT8 vaccinated rTg4510 mice showed no significant reductions in pathological tau. All graphs display mean ± SEM. Student’s t-test (b, d, f). p < 0.05*; p < 0.001***; p < 0.0001****. Qβ Control (n = 5), Qβ-AT8 (n = 7), Qβ-PHF1 (n = 8).
